IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
Jerome H. Kim appointed as Director General of IVI
Jerome H. Kim appointed as Director General of IVI
SEOUL, REPUBLIC OF KOREA – The International Vaccine Institute (IVI), a Seoul-based non-profit international organization devoted to research in vaccine development and delivery for the developing world, announced the appointment of Jerome H. Kim, M.D., as the organization’s Director General, effective early 2015.
“Jerome’s scientific knowledge, technical expertise, and organizational and leadership skills, make him an ideal fit for the position,” said Prof. Adel A. Mahmoud, Chair of IVI’s Board of Trustees. “With his distinguished track record in vaccine research & development and passionate commitment to vaccines, he will bring strong scientific leadership and management of a dynamic international organization.”
“I am honored by the opportunity to join IVI, and I look forward to working with the IVI team, partners, and donors,” said Dr. Kim, “IVI is a very unique organization. Its breadth in vaccinology spans research & development, epidemiology, technology transfer, policy and access. Together, we will improve the health and wellbeing of the world’s poorest populations through fulfilling IVI’s mission – to discover, develop, and deliver safe, effective and affordable vaccines for developing nations.”
A medical doctor by training and a colonel in the United States Army Medical Corps, Dr. Kim is a recognized leader in HIV research and HIV vaccine development. He was named one of “The 50 Most Influential People in Vaccines” in 2014 by the vaccine industry organization Vaccine Nation. Dr. Kim was the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at the U.S. Military HIV Research Program (MHRP) and the U.S. Army's Project Manager for the HIV Vaccines and Advanced Concepts Evaluation and Staging.
He was the U.S. Army lead for the Phase III HIV vaccine trial (RV144), which was the first to show that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination. His research interests include HIV molecular epidemiology, host genetics, and HIV vaccine development. He has authored over 140 publications.
Dr. Kim is a Professor of Medicine at the Uniformed Services University of the Health Sciences and is a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He received his M.D. from the Yale University School of Medicine, and completed his training in Internal Medicine and fellowship in Infectious Diseases at Duke University Medical Center.
“As IVI’s host country and donor, the Republic of Korea is pleased with the appointment of Dr. Kim,” said Dr. Young-Soon Kang, Director General of the International Cooperation Bureau, South Korea’s Ministry of Education, “Dr. Kim is a well-respected and internationally renowned scientist and leader. Under his leadership, IVI is well-positioned to move to the next level, not only in research but also as an organization.”
“IVI has been an important long-term partner and grantee of the Bill & Melinda Gates Foundation,” added Dr. Anita Zaidi, Director of Enteric and Diarrheal Diseases at the Bill & Melinda Gates Foundation, “Therefore we are delighted that Dr. Jerome Kim will be the next Director General of IVI. We look forward to the greater contributions that IVI will make in developing and deploying vaccines for underserved populations under his leadership.”
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.
Tae Kyung Byun
Public Awareness/Advocacy Officer, IVI
Phone: +82-2-872-2801 (Ext. 159)